2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P4836A
    LL-37 FK-13 TFA 98.60%
    LL-37 FK-13 TFA is the TFA salt form of LL-37 FK-13 (HY-P4836). LL-37 FK-13 TFA is an antimicrobial agent, that inhibits Trichomonas vaginalis. LL-37 FK-13 TFA exhibits minimal hemolytic effects on human erythrocytes and low cytotoxicity to human fibroblasts.
    LL-37 FK-13 TFA
  • HY-P5057B
    5-FAM-Ahx-LL-37 TFA 98.06%
    5-FAM-Ahx-LL-37 TFA is a 5-FAM (HY-66022) labeled LL-37, human (HY-P1222). The carboxyfluorescein group is attached via a 6-carbon spacer, 6-Aminohexanoic acid (Ahx, HY-B0236). LL-37, human is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity.
    5-FAM-Ahx-LL-37 TFA
  • HY-P5313A
    Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr acetate 98.03%
    Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr acetate is a DEN protease substrate, which can be used in research related to dengue virus (drug development).
    Abz-Nle-Lys-Arg-Arg-Ser-3-(NO2)Tyr acetate
  • HY-P99425
    Afelimomab 156227-98-4
    Afelimomab (MAK 195F) is an anti-tumor necrosis factor monoclonal antibody. Afelimomab can be used for the research of sepsis.
    Afelimomab
  • HY-P99467
    Beludavimab 2423016-74-2
    Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM.
    Beludavimab
  • HY-P99551
    Tosatoxumab 1374419-41-6
    Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992).
    Tosatoxumab
  • HY-P99571
    Tefibazumab 521079-87-8 99.90%
    Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections.
    Tefibazumab
  • HY-P99584
    Suvizumab 914257-21-9 ≥99.0%
    Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection.
    Suvizumab
  • HY-P99608
    Exbivirumab 569658-80-6
    Exbivirumab is a monoclonal antibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant.
    Exbivirumab
  • HY-P99686
    Larcaviximab 1792982-56-9
    Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody.
    Larcaviximab
  • HY-P99767
    Olendalizumab 2210314-30-8
    Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus.
    Olendalizumab
  • HY-P99837
    Dafsolimab 2367001-71-4
    Dafsolimab (SPV-T3a) is a Mouse IgG2b monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD).
    Dafsolimab
  • HY-P99937
    Elipovimab 2101210-43-7
    Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells
    Elipovimab
  • HY-U00092
    BAY-Y 3118 151213-16-0 99.22%
    BAY-Y 3118 is a quinolone antibacterial agent. BAY-Y 3118 has a broad antibacterial spectrum in vitro. BAY-Y 3118 exhibits high activity against gram-positive cocci and anaerobes. BAY-Y 3118 shows moderate activity against Enterobacteriaceae and Pseudomonas aeruginosa. BAY-Y 3118 can be used in the research of infectious diseases.
    BAY-Y 3118
  • HY-U00097
    L-4-Oxalysine hydrochloride 118021-35-5 99.95%
    L-4-Oxalysine hydrochloride is a natural product isolated from the culture media of Streptomyces roseovirdofuscus in China which has shown antitumor activities.
    L-4-Oxalysine hydrochloride
  • HY-U00265
    3-CPs 20073-24-9
    3-CPs is a monofunctional furanocoumarin and a photoprotective agent targeting Staphylococcus aureus DNA, possessesing anti-UVB lethal activity. 3-CPs competitively intercalates into DNA, forming exclusively 4',5'-furan-side mono-adducts upon UVB irradiation, and irreversibly inhibits the formation of cyclobutane pyrimidine dimers. 3-CPs prevents UVB-induced DNA damage by preferentially binding to strong (AT)n sites within the DNA, without inducing lethal interstrand DNA cross-links; the limited number of mono-adducts it induces can be efficiently repaired by bacteria. 3-CPs holds potential for use in the development of photoprotective formulations for skin diseases, as well as in studies investigating bacterial DNA photodamage repair mechanisms and the optimization of photochemotherapy safety.
    3-CPs
  • HY-100603A
    (S)-GSK-F1 1384097-27-1 98.01%
    (S)-GSK-F1 (Compound 28) is an inhibitor for type III phosphatidylinositol 4-kinase α (PI4KIIIα). (S)-GSK-F1 inhibits PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ and PI3Kδ with pIC50 of 8.3, 6.0, 5.6, 5.6, 5.1 and 5.6, respectively. (S)-GSK-F1 exhibits anti-hepatitis C virus (HCV) activity through inhibition of HCV replication. (S)-GSK-F1 exhibits moderate pharmacokinetic characters in rat model.
    (S)-GSK-F1
  • HY-101441A
    ST-193 hydrochloride 2320274-72-2 98.76%
    ST-193 hydrochloride is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC50 values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.
    ST-193 hydrochloride
  • HY-10394S1
    Linezolid-d8 1032182-14-1 99.74%
    PNU-100766-d8 is deuterated labeled Linezolid (HY-10394). Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics.
    Linezolid-d8
  • HY-105084A
    Lubeluzole dihydrochloride 144665-09-8 99.00%
    Lubeluzole dihydrochloride is the dihydrochloride salt of Lubeluzole (HY-105084). Lubeluzole dihydrochloride is the S-isomer of benzothiazole derivative. Lubeluzole dihydrochloride can inhibit glutamate release, glutamate-activated NO synthesis and block voltage-gated Sodium Channel and Calcium Channel. Lubeluzole dihydrochloride exhibits anti-ischemic and neuroprotective effects. Lubeluzole dihydrochloride also shows anti-bacterial and anti-diarrheal potential. Lubeluzole dihydrochloride can inhibit cardiac sodium channel and prolong cardiac action potential. Lubeluzole dihydrochloride can inhibit cancer cells proliferation and invasion and shows chemosensitizing effect. Lubeluzole dihydrochloride can be used for the researches of cancer, infection, neurological and cardiovascular disease such as stroke, infectious diarrhea and ovarian.
    Lubeluzole dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity